FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3009698914> ?p ?o ?g. }

• W3009698914 endingPage "e1145" @default.
• W3009698914 startingPage "650" @default.
• W3009698914 abstract "Abstract Trial Information Click here to access other published clinical trials. Lessons Learned Results of the KEYNOTE-032 study showed that the safety and pharmacokinetic profiles of pembrolizumab in Chinese patients were comparable with those observed in international studies, and antitumor activity was encouraging. These data support further evaluation of pembrolizumab to improve clinical outcomes in Chinese patients with advanced non-small cell lung cancer. Background The KEYNOTE-032 study evaluated pembrolizumab pharmacokinetics and clinical outcomes in Chinese patients with locally advanced and/or metastatic non-small cell lung cancer (NSCLC) and prior treatment failure and/or ineligibility for standard therapy. Methods Patients were randomized 1:1:1 to pembrolizumab 2 mg/kg, 10 mg/kg, or 200 mg every 3 weeks (up to 35 cycles). Safety and pharmacokinetics were primary endpoints; antitumor activity was a secondary endpoint. Results A total of 42 of 44 randomized patients received pembrolizumab treatment (2 mg/kg, n = 14; 10 mg/kg, n = 13; 200 mg, n = 15). Treatment-related adverse events (AEs) occurred in 29 of 42 (69%) patients (grade 3–4, 4/42 [10%]); 5 (12%) had immune-mediated AEs and infusion reactions. Pembrolizumab single dose half-life following 2 mg/kg, 10 mg/kg, and 200 mg was 15.1, 15.8, and 12.3 days, respectively. Serum exposure at the doses studied (range, 2–10 mg/kg) was approximately linear; steady-state area under the curve0–21 days (95% confidence interval [CI]) was 730.9 (627.4–851.6), 2,819.2 (2,009.4–3,955.4), and 931.0 (724.4–1,196.6) μg•day/mL, respectively. After 7.9 (range, 0.7–13.1) months median follow-up overall, objective response rate was 14.3% (95% CI, 5.4%–28.5%); median progression-free survival was 2.1 (95% CI, 2.1–4.2) months, and median overall survival was not reached (95% CI, 6.6 months–not reached). Conclusion Pembrolizumab had manageable toxicity, linear serum exposure, and encouraging antitumor activity in Chinese patients with advanced NSCLC." @default.
• W3009698914 created "2020-03-13" @default.
• W3009698914 creator A5003608372 @default.
• W3009698914 creator A5020252828 @default.
• W3009698914 creator A5023899283 @default.
• W3009698914 creator A5046131158 @default.
• W3009698914 creator A5052901056 @default.
• W3009698914 creator A5062034817 @default.
• W3009698914 creator A5063454074 @default.
• W3009698914 creator A5066716873 @default.
• W3009698914 creator A5067183622 @default.
• W3009698914 creator A5067253443 @default.
• W3009698914 creator A5070121957 @default.
• W3009698914 date "2020-03-05" @default.
• W3009698914 modified "2023-10-02" @default.
• W3009698914 title "KEYNOTE-032: A Randomized Phase I Study of Pembrolizumab in Chinese Patients with Advanced Non-Small Cell Lung Cancer" @default.
• W3009698914 cites W1982488143 @default.
• W3009698914 cites W2010121426 @default.
• W3009698914 cites W2019607817 @default.
• W3009698914 cites W2124427232 @default.
• W3009698914 cites W2150048477 @default.
• W3009698914 cites W2160834915 @default.
• W3009698914 cites W2198093519 @default.
• W3009698914 cites W2470450296 @default.
• W3009698914 cites W2527905628 @default.
• W3009698914 cites W2560676896 @default.
• W3009698914 cites W2612703804 @default.
• W3009698914 cites W2768379094 @default.
• W3009698914 cites W2925446385 @default.
• W3009698914 cites W2943298863 @default.
• W3009698914 cites W2943787040 @default.
• W3009698914 doi "https://doi.org/10.1634/theoncologist.2020-0067" @default.
• W3009698914 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7418348" @default.
• W3009698914 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32134163" @default.
• W3009698914 hasPublicationYear "2020" @default.
• W3009698914 type Work @default.
• W3009698914 sameAs 3009698914 @default.
• W3009698914 citedByCount "10" @default.
• W3009698914 countsByYear W30096989142020 @default.
• W3009698914 countsByYear W30096989142021 @default.
• W3009698914 countsByYear W30096989142022 @default.
• W3009698914 countsByYear W30096989142023 @default.
• W3009698914 crossrefType "journal-article" @default.
• W3009698914 hasAuthorship W3009698914A5003608372 @default.
• W3009698914 hasAuthorship W3009698914A5020252828 @default.
• W3009698914 hasAuthorship W3009698914A5023899283 @default.
• W3009698914 hasAuthorship W3009698914A5046131158 @default.
• W3009698914 hasAuthorship W3009698914A5052901056 @default.
• W3009698914 hasAuthorship W3009698914A5062034817 @default.
• W3009698914 hasAuthorship W3009698914A5063454074 @default.
• W3009698914 hasAuthorship W3009698914A5066716873 @default.
• W3009698914 hasAuthorship W3009698914A5067183622 @default.
• W3009698914 hasAuthorship W3009698914A5067253443 @default.
• W3009698914 hasAuthorship W3009698914A5070121957 @default.
• W3009698914 hasBestOaLocation W30096989141 @default.
• W3009698914 hasConcept C112705442 @default.
• W3009698914 hasConcept C121608353 @default.
• W3009698914 hasConcept C126322002 @default.
• W3009698914 hasConcept C143998085 @default.
• W3009698914 hasConcept C168563851 @default.
• W3009698914 hasConcept C197934379 @default.
• W3009698914 hasConcept C203092338 @default.
• W3009698914 hasConcept C2776256026 @default.
• W3009698914 hasConcept C2777701055 @default.
• W3009698914 hasConcept C2780057760 @default.
• W3009698914 hasConcept C44249647 @default.
• W3009698914 hasConcept C535046627 @default.
• W3009698914 hasConcept C71924100 @default.
• W3009698914 hasConcept C90924648 @default.
• W3009698914 hasConceptScore W3009698914C112705442 @default.
• W3009698914 hasConceptScore W3009698914C121608353 @default.
• W3009698914 hasConceptScore W3009698914C126322002 @default.
• W3009698914 hasConceptScore W3009698914C143998085 @default.
• W3009698914 hasConceptScore W3009698914C168563851 @default.
• W3009698914 hasConceptScore W3009698914C197934379 @default.
• W3009698914 hasConceptScore W3009698914C203092338 @default.
• W3009698914 hasConceptScore W3009698914C2776256026 @default.
• W3009698914 hasConceptScore W3009698914C2777701055 @default.
• W3009698914 hasConceptScore W3009698914C2780057760 @default.
• W3009698914 hasConceptScore W3009698914C44249647 @default.
• W3009698914 hasConceptScore W3009698914C535046627 @default.
• W3009698914 hasConceptScore W3009698914C71924100 @default.
• W3009698914 hasConceptScore W3009698914C90924648 @default.
• W3009698914 hasIssue "8" @default.
• W3009698914 hasLocation W30096989141 @default.
• W3009698914 hasLocation W30096989142 @default.
• W3009698914 hasOpenAccess W3009698914 @default.
• W3009698914 hasPrimaryLocation W30096989141 @default.
• W3009698914 hasRelatedWork W2032912323 @default.
• W3009698914 hasRelatedWork W2372561159 @default.
• W3009698914 hasRelatedWork W2390152934 @default.
• W3009698914 hasRelatedWork W3041652591 @default.
• W3009698914 hasRelatedWork W3089163820 @default.
• W3009698914 hasRelatedWork W3177224496 @default.
• W3009698914 hasRelatedWork W4256514411 @default.
• W3009698914 hasRelatedWork W4322775203 @default.
• W3009698914 hasRelatedWork W4353086495 @default.
• W3009698914 hasRelatedWork W4386083912 @default.

• next